WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 528822
CAS#: 865625-56-5 (sodium)
Description: Ladarixin Sodium is an Chemokine CXCR antagonist potentially for the treatment of type I diabetes.
MedKoo Cat#: 528822
Name: Ladarixin Sodium
CAS#: 865625-56-5 (sodium)
Chemical Formula: C11H11F3NNaO6S2
Molecular Weight: 397.315
Elemental Analysis: C, 33.25; H, 2.79; F, 14.35; N, 3.53; Na, 5.79; O, 24.16; S, 16.14
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: DF-2156A; DF2156A; DF 2156A; DF-2156; DF2156; DF 2156; Ladarixin Sodium.
IUPAC/Chemical Name: sodium (R)-(methylsulfonyl)(2-(4-(((trifluoromethyl)sulfonyl)oxy)phenyl)propanoyl)amide
InChi Key: QICAUCDBOAKDNS-OGFXRTJISA-M
InChi Code: InChI=1S/C11H12F3NO6S2.Na/c1-7(10(16)15-22(2,17)18)8-3-5-9(6-4-8)21-23(19,20)11(12,13)14;/h3-7H,1-2H3,(H,15,16);/q;+1/p-1/t7-;/m1./s1
SMILES Code: C[C@H](C1=CC=C(OS(=O)(C(F)(F)F)=O)C=C1)C([N-]S(=O)(C)=O)=O.[Na+]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 397.315 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Citro A, Valle A, Cantarelli E, Mercalli A, Pellegrini S, Liberati D, Daffonchio L, Kastsiuchenka O, Ruffini PA, Battaglia M, Allegretti M, Piemonti L. CXCR1/2 inhibition blocks and reverses type 1 diabetes in mice. Diabetes. 2015 Apr;64(4):1329-40. doi: 10.2337/db14-0443. Epub 2014 Oct 14. PubMed PMID: 25315007.
2: Kemp DM, Pidich A, Larijani M, Jonas R, Lash E, Sato T, Terai M, De Pizzol M, Allegretti M, Igoucheva O, Alexeev V. Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment. Oncotarget. 2017 Jan 24. doi: 10.18632/oncotarget.14803. [Epub ahead of print] PubMed PMID: 28129639.
3: Carreira EU, Carregaro V, Teixeira MM, Moriconi A, Aramini A, Verri WA Jr, Ferreira SH, Cunha FQ, Cunha TM. Neutrophils recruited by CXCR1/2 signalling mediate post-incisional pain. Eur J Pain. 2013 May;17(5):654-63. doi: 10.1002/j.1532-2149.2012.00240.x. Epub 2012 Nov 7. PubMed PMID: 23132735.